The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug ...

Boehringer Ingelheim's attempt to develop the first drug therapy for impaired cognitive function in schizophrenia, a core feature of the illness, has suffered what looks like a terminal setback.

Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

Boehringer Ingelheim is to collaborate with UK biotech Autifony Therapeutics to develop an early-stage schizophrenia drug and other compounds. Although central nervous system diseases are a focus ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Zeit Aktuelle Nachrichten 17.01. Boehringer drug for brain fog in schizophrenia fails trial 16.01. Boehringer's phase 3 schizophrenia program misses primary goal 16.01. Boehringer Ingelheim ...